While the control of cancer‐induced skeletal muscle protein degradation is widely studied (Hardee et al., 2017; White et al., 2011; White, Puppa, Gao, et al., 2013), there has been a focus on the classical FOXO3a control of E3 ligases, Atrogin‐1, and MuRF‐1, driven by inflammatory signaling (Blackwell et al., 2018; Reed et al., 2012; White et al., 2011). This evidence concerns the gene FOXO3 and cancer.